MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purposes of this phase I portion are; 1) to evaluate the safety and tolerability of
MK2461 and 2) to determine the recommended phase 2 dose or doses of MK2461.
The purpose of the phase II portion is to evaluate the anti-tumor efficacy of MK2461.